Compare DOMH & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOMH | BRTX |
|---|---|---|
| Founded | 1967 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.2M | 9.7M |
| IPO Year | N/A | N/A |
| Metric | DOMH | BRTX |
|---|---|---|
| Price | $4.52 | $1.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 319.7K | 31.5K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | ★ 14.55% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 9.19 | N/A |
| Revenue | ★ $99,588,000.00 | $383,400.00 |
| Revenue This Year | N/A | $112.14 |
| Revenue Next Year | N/A | $139.81 |
| P/E Ratio | $0.50 | ★ N/A |
| Revenue Growth | ★ 691.07 | 1.70 |
| 52 Week Low | $0.83 | $0.98 |
| 52 Week High | $13.58 | $2.55 |
| Indicator | DOMH | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.51 | 40.10 |
| Support Level | $4.20 | $1.04 |
| Resistance Level | $4.70 | $1.23 |
| Average True Range (ATR) | 0.28 | 0.09 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 54.47 | 34.78 |
Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.